Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01049113 · ClinicalTrials.gov registry record · Phase 1
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
A Phase 1 study, sponsored by Traws Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01049113: Clinical Trial Phase 1 study, sponsored by Traws Pharma.
NCT01049113 is a Phase 1 study that was terminated before completion, run by Traws Pharma. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01049113, a Phase 1 study, was terminated before completion, sponsored by Traws Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is an open-label, dose-escalation Phase 1 study of the investigational agent, ON 013105. In laboratory animal studies, ON 013105 has demonstrated anti-cancer activity. The purpose of this study is to determine the highest dose of ON 013105 that can be given safely in patients with relapsed/refractory Lymphoma or B-cell Acute Lymphocytic Leukemia (Philadelphia chromosome negative). Patients will receive weekly 2-hour IV infusions of ON 013105 at higher and higher doses until intolerable side effects are observed. It is important to know the highest safe dose so additional studies can be done.
Interventions
- DRUG ON 013105
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-11 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Why NCT01049113 stopped before completion
NCT01049113 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which ON 013105 is the first listed.
NCT01049113 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01049113 about?
NCT01049113 is a clinical study titled "Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia". This is an open-label, dose-escalation Phase 1 study of the investigational agent, ON 013105. In laboratory animal studies, ON 013105 has demonstrated anti-cancer activity. The purpose of this study is to determine the highest dose of ON 013105 that can be given safely in patients with relapsed/refr...
What is the current status of trial NCT01049113?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2009-11. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01049113?
The interventions under investigation include: ON 013105 (DRUG).
Who is sponsoring clinical trial NCT01049113?
This trial is sponsored by Traws Pharma, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01049113's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia